SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
|
|
- Lawrence Grant
- 5 years ago
- Views:
Transcription
1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 SYNTHETIC BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.) 155 Gibbs Street, Suite 412, Rockville, MD (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (734) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))
2 Item Regulation FD Disclosure Beginning on May 14, 2013, Synthetic Biologics, Inc. (the Company ), will be making several investor presentations during the next few weeks. In connection with the presentations, the Company intends to discuss the slide presentation furnished as Exhibit 99.1 hereto, which is incorporated herein by reference. The slide presentation attached as Exhibit 99.1 to this Report includes safe harbor language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release are forwardlooking rather than historical. The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits. Item Financial Statements and Exhibits (d) Exhibits The following exhibit is being filed as part of this Report. Exhibit Number Description 99.1 Presentation materials to be provided at Synthetic Biologics, Inc. s investor presentations
3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNTHETIC BIOLOGICS, INC. Date: May 14, 2013 By: /s/ C. Evan Ballantyne Name: C. Evan Ballantyne Title: Chief Financial Officer
4 EXHIBIT INDEX Exhibit Number Description 99.1 Presentation materials to be provided at Synthetic Biologics, Inc. s investor presentations
5 May 14, 2013 NYSE MKT: SYN EXHIBIT 99.1
6 Forward - Looking Statements This presentation includes forward - looking statements on Synthetic Biologics current expectations and projections about future events. In some cases forward - looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes, "estimates, indicates, and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our clinical trials, our establishment of collaborations and our execution of our growth strategy. The forward - looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward - looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics forward - looking statements include, among others, a failure of our product candidates to be demonstrably safe and effective, a failure to initiate clinical trials and if initiated, a failure to achieve the desired results, a failure to obtain regulatory approval for our product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for the specific indications, a lack of acceptance of our product candidates in the marketplace, a failure of us to become or remain profitable, a failure to establish collaborations, our inability to obtain or maintain the capital or grants necessary to fund our research and development activities, a loss of any of our key scientists or management personnel, and other factors described in Synthetic Biologics report on Form 10 - K for the year ended December 31, 2012, subsequent Form 10 - Qs and any other filings with the SEC. The information in this presentation is provided only as of the date presented, and Synthetic Biologics undertakes no obligation to update any forward - looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law. 2 NYSE MKT: SYN
7 Investment Proposition Building portfolio of biologics for the prevention and treatment of serious infectious diseases Innovative, first - in - class product candidates Large markets Proof - of - concept portfolio Clinical - stage Multiple sclerosis (MS) Phase II (potential partnering opportunity) Prevention of Clostridium difficile (C. difficile ) infections Discovery/preclinical stage Pertussis infections (whooping cough) Acinetobacter infections Strategic collaborations with Intrexon Corporation Private biotechnology company led by CEO, RJ Kirk Experienced management team and advisors 3 NYSE MKT: SYN NYSE MKT: SYN
8 Management Team 4 Jeffrey Riley, CEO Pfizer, Nichols Institute (Quest), SmithKline Beecham, QIC C. Evan Ballantyne, CFO Clinical Data, Inc., Avedro, ZymeQuest, ACNielsen, IMS John Monahan, Ph.D., EVP R&D Avigen, Somatix, Triton Biosciences, Hoffman - LaRoche Carol Reed, M.D., SVP Clinical/Regulatory Clinical Data, Inc., Genaissance Pharmaceuticals, Inc., Bayer Pharmaceuticals, Inc. Michael Kaleko, M.D., Ph.D., SVP R&D Genetic Therapy, Inc. (Novartis), Advanced Vision Therapies (currently known as Wellstat Ophthalmics ) NYSE MKT: SYN
9 Product Pipeline 5 NYSE MKT: SYN * - SYN - 004, 2 nd generation oral enzyme candidate under development based on 1 st generation candidate (P1A) Phase II results I - Intrexon collaboration design, engineering and optimization of lead candidates T - The University of Texas at Austin antibody research Therapeutic Area Product Candidate Biologic Agent/ Drug Compound Discovery Preclinical Phase I Phase II Phase III Relapsing - remitting m ultiple sclerosis Trimesta TM Oral estriol Cognitive dysfunction in multiple sclerosis Trimesta TM Oral estriol C. difficile infection prevention SYN - 004* Oral enzyme Pertussis (whooping cough) SYN I,T Monoclonal antibody Acinetobacter infections SYN I Monoclonal antibody
10 MS: Market 400,000 MS patients in U.S. (~2.1 million worldwide) 1 $14.1 billion current estimated worldwide sales 2 Trimesta TM opportunity Oral add - on MS therapy 6 NYSE MKT: SYN Teva/Copaxone $ % Biogen Idec/Avonex $ % Merck KGaA/Rebif $ % Biogen Idec/Tysabri $ % Bayer/Betaseron $ % Novartis/Extavia $ % Novartis/Gilenya $ %
11 MS: Historical Efficacy of Estriol Pregnancy Hormone Linked to decreased MS relapse rates Estriol Hormone produced by placenta during pregnancy with highest level in 3 rd trimester Solid safety profile (approved in Europe/Asia for 40+ years) Landmark study published in New England Journal of Medicine 3 Study of 254 women diagnosed with MS prior to pregnancy Relapse rates: Significantly reduced in 3 rd trimester of pregnancy (p<0.001) * Significantly increased three months post - partum (p<0.001) * 7 * C ompared to pre - pregnancy levels NYSE MKT: SYN
12 MS: Relapsing - Remitting MS Phase II Clinical Trial of Trimesta TM (oral estriol) Multi - center, investigator - initiated, randomized, double - blind, placebo - controlled trial 4 Comparing relapse rates over 2 years of oral Trimesta TM vs. placebo All patients treated with Copaxone as standard of care Trial status Enrollment complete: 164 female patients at 15 U.S. centers Final patient, final visit expected end of January 2014 Topline results expected 1H 2014 $ 8 million + in grant funding supporting trial Principal investigator: Rhonda Voskuhl, M.D., Professor of Neurology, Director of the UCLA MS Program Seeking to monetize Trimesta TM 8 Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd. NYSE MKT: SYN
13 Emerging Worldwide Crisis 9 SYN building portfolio of biologics for serious infectious diseases Infections were the second leading cause of death worldwide in 2002, killing nearly 15 million people almost 1 in 3 deaths across the globe Multidrug - resistant microbes infect more than 2 million Americans each year Brad Spellberg, M.D., Rising Plague 5 NYSE MKT: SYN
14 Current Market Limited Solutions Significant Unmet Medical Needs Limited Big Pharma Investment SYN Products Targeted Biologics Novel Antibacterial R&D GAIN Act Revolutionize Infectious Disease Treatment 10 NYSE MKT: SYN SYN infectious disease strategy Large and growing markets Infectious disease outbreaks increasing Widespread multidrug - resistant pathogens Additional market exclusivity Fast track Accelerated NDA reviews Limited patient population opportunities
15 11 24 million patients administered IV antibiotics annually in the U.S million patients infected with C. diff annually 7 Patients with C. diff hospitalized extra days 8, costing more than $8.2 billion annually 9 30,000 C. diff - related deaths annually 10 IV antibiotics may be excreted into GI tract where they can upset the natural balance of the microbiome This imbalance can result in the overgrowth of disease - causing bacteria such as C. diff Toxigenic C. diff causes diarrhea, pseudomembranous colitis and may result in death C. d ifficile (C. diff) Infections: Market Leading cause of hospital - acquired infections NYSE MKT: SYN 15 million Americans administered IV β - lactam antibiotics in
16 12 SYN - 004: Co - Administered with Antibiotics Prophylactic treatment for prevention of C. diff infections Oral enzyme product to be co - administered with IV β - lactam antibiotics Remain within the intestine to degrade certain IV β - lactam antibiotics Preventative treatment expected to protect the healthy microflora from the overgrowth of C. diff Phase I and II studies of 1st generation candidate* demonstrated safety, tolerability and efficacy when co - administered with certain penicillins SYN - 004, a 2 nd generation product intended for a broader spectrum of activity including, penicillins plus most cephalosporins ( β - lactam antibiotics) In 2012, over 13 million unique patients were treated with IV β - lactams that may be covered with SYN SYN composition of matter patent protection through 2031 * P1A is 1 st generation candidate NYSE MKT: SYN There are currently no approved products for the prevention of C. difficile infections
17 SYN - 004: Co - Administered with Antibiotics Intended to neutralize effects of β - lactam antibiotics in GI tract 13 Patient hospitalized with PRIMARY infection ( eg. pneumonia) Administer IV β - lactam antibiotic for primary infection SYN eliminates the antibiotic, protecting native microflora and prevent C. diff infection Co - administer oral SYN with IV β - lactam antibiotic Antibiotic enters the GI tract leading to C. diff infection Unprotected GI tract Protected GI tract NYSE MKT: SYN
18 Pertussis Infections : Market Millions of whooping cough cases globally per year Increasing incidence at a 60 - year high in U.S. 13,14 ~41,000 cases per year in the U.S. 15 Current vaccination protocols are not effective due to: Delayed infant vaccination Non - compliance 1990s vaccine protection wearing off 50 million worldwide cases of whooping cough each year ,000 deaths worldwide 16 (Primarily young, unvaccinated infants) SYN mab in development Intended to neutralize pertussis toxin Collaboration with Intrexon R ights to research and pending patents from The University of Texas at Austin Plan to pursue third - party funding and alternative commercialization strategies 14 NYSE MKT: SYN
19 Acinetobacter Infections : Market Multidrug - resistant gram - negative bacteria M ortality rates as high as 43% reported 17 Billion dollar market opportunity 18 Survives on dry surfaces for up to 36 days Survives twice as long as non - biofilm - forming pathogens 19 Acinetobacter infection profile 2.6% of hospital acquired infections % of bloodstream infections 20 7% of ICU respiratory tract infections 20 May infect many organisms including lungs, heart, urinary tract, central nervous system, and skin and soft tissues Increasing cause of trauma - related infections in wounded military personnel and victims of natural disasters 21 Collaboration with Intrexon Plan to pursue third - party funding and alternative commercialization strategies 15 NYSE MKT: SYN
20 Corporate Snapshot Current Price : $1.42 (as of 5/10/13) 52 Week Range: $ $ 2.55 Average Volume (3 months): 66,202 Shares Outstanding: ~44.7 million (as of 3/27/13) Market Capitalization: ~$63 million Cap Structure: Common, no debt, no preferred Cash: ~$8.7 million (as of 3/27/13) Offices in Rockville, Maryland 16 NYSE MKT: SYN NYSE MKT: SYN
21 Recent IPOs in the Infectious Disease Space 17 Company Name IPO Date Lead Candidate Market Cap* Tetraphase Pharmaceuticals, Inc. March 2013 Phase II: eravacycline - intra - abdominal infections (IV) $158M Cempra, Inc. February 2012 Phase III: respiratory tract infections; bacterial urethritis comprising gonorrhea; acute bacterial skin and skin structure infections $164M Durata Therapeutics July 2012 Phase III: antibiotic for acute bacterial skin and skin structure infections (IV) $180M Enanta Pharmaceuticals, Inc. March 2013 Phase III: Inhibitor - Hep C & HCV $317M Chimerix, Inc. April 2013 Phase II: CMV infection; adenovirus $500M * Per Yahoo Finance May 2, 2013 NYSE MKT: SYN
22 18 Upcoming Milestones NYSE MKT: SYN Phase II relapsing - remitting MS clinical trial Final patient, final visit (end of January 2014) Topline results ( 1H 2014) SYN oral enzyme preventative treatment for C. diff Initiate cgmp manufacturing (3Q 2013) Initiate clinical trials (2H 2014) mab for Pertussis infections Initiate small animal study (3Q 2013) Initiate large animal study (4Q 2013) [IND - enabling study] mabs for Acinetobacter infections Generate panel of antibodies (ongoing)
23 May FINAL May 14, 2013 NYSE MKT: SYN
24 References Slide 6: 1 National Multiple Sclerosis Society. 2 Credit Suisse. Multiple Sclerosis - Evolution or Revolution Report. March 18, Slide 7 : 3 Pr egnancy I n M ultiple S clerosis (PRIMS) Study; Confavreux, C., Hutchinson, M., Hours, M.M., Cortinvis - Tourniaire, P., Moreau, T., and the Pregnancy in MS Group (1998). Rate of Pregnancy - Related Relapse in Multiple Sclerosis. New England Journal of Medicine, 339, Slide 8 : 4 Slide 9 : 5 Spellberg, B. Rising Plague: The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them. Copyright Slide 11 : 6-7 This information is an estimate derived from the use of information under license from the following IMS Health Incorporated inf ormation service: CDM Hospital database for full year IMS expressly reserves all rights, including rights of copying, distribution and republic ation. 8 (APIC) National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities. November 11, hospitalacquiredinfections.blogspot.com/2008/12/november association - for.html. 9 Agency for Healthcare Research and Quality. Healthcare and Cost Utilization Project. Statistical Brief #124. Clostridium difficile Infections (CDI) in Hospital Stays, January Available at - us.ahrq.gov/reports/statbriefs/sb124.pdf. 10 U.S. Department of Health & Human Services. Agency for Healthcare Research and Quality. January 25, Available at Accessed November 5, This information is an estimate derived from the use of information under license from the following IMS Health Incorporated inf ormation service: CDM Hospital database for full year IMS expressly reserves all rights, including rights of copying, distribution and republic ation. Slide 12 : 12 This information is an estimate derived from the use of information under license from the following IMS Health Incorporated inf ormation service: CDM Hospital database for full year IMS expressly reserves all rights, including rights of copying, distribution and republic ation. 20 NYSE MKT: SYN
25 References 21 Slide 14 : 13 Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW, Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, JAMA, 2012 Nov 28;308(20): Centers for Disease Control and Prevention. Pertussis Epidemic Washington, Morbidity and Mortality Weekly Report. July 20, Centers for Disease Control and Prevention Provisional Pertussis Surveillance Report. January 4, World Health Organization. Pertussis: Immunization surveillance, assessment and monitoring. http :// Slide 15 : 17 Falagas, ME, Bliziotis, LA, and Siempos, II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case - control studies. Critical Care 2006, 10:R Barrett, L. Former VP of US Marketing and Global Business Manager Infectious Diseases at Wyeth. Guest Blog, Antibiotic Market s a nd SPLU. - theperfectstorm.blogspot.com/2012/03/antibiotic - markets - and - splu - guest.html. March 20, Espinal P, Martí S, Vila J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J Hosp Infect Jan; 80(1): Epub 2011 Oct Jones, M, et al. Emerging resistance among bacterial pathogens in the intensive care unit a European and North American Survei llance study ( ). Ann Clin Microbiol Antimicrob ; 3(14).; Wisplinghoff, H, et al. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin Infect Dis 2004; 39(3): ; Wachter, K. Step Aside, MRSA, Here Comes Acinetobacter. OB. GYN. News, January 15, Camp, C and Tatum, OL. A Review of Acinetobacter baumannii as a Highly Successful Pathogen in Times of War. LABMEDICINE. November 2010, Vol. 41, Number 11. NYSE MKT: SYN
SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationSYNTHETIC BIOLOGICS, INC.
SYNTHETIC BIOLOGICS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 05/12/14 Address 155 GIBBS STREET SUITE 412 ROCKVILLE, MD 20850 Telephone (734) 332-7800 CIK 0000894158
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationPROSPECTUS SUPPLEMENT NO. 12 SYNTHETIC BIOLOGICS, INC. 112,573 Shares of Common Stock
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-180562 December 6, 2012 PROSPECTUS SUPPLEMENT NO. 12 SYNTHETIC BIOLOGICS, INC. 112,573 Shares of Common Stock This prospectus supplement
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationArsanis, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationORGANOVO HOLDINGS, INC.
ORGANOVO HOLDINGS, INC. FORM 8-K (Current report filing) Filed 11/18/14 for the Period Ending 11/16/14 Address 6275 NANCY RIDGE DRIVE SUITE 110 SAN DIEGO, CA 92121 Telephone 858-550-9994 CIK 0001497253
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFORM 8-K. SUNSHINE BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter)
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationFORM 8-K. DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP. Form: 8-K. Date Filed:
SECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP Form: 8-K Date Filed: 2018-04-23 Corporate Issuer CIK: 927761 Copyright 2018, Issuer Direct Corporation. All Right Reserved. Distribution of
More informationCatching the Bug for Novel Antibiotics: Roundtable Conference
Leerink Swann & Company Catching the Bug for Novel Antibiotics: Roundtable Conference March 6, 2007 Nebojsa Janjic Chief Scientific Officer We are providing this information as of February 12, 2007 and
More informationSYNTHETIC BIOLOGICS (NYSE-MKT: SYN)
INITIATION REPORT Biotechnology Industry February 5, 2013 SYNTHETIC BIOLOGICS (NYSE-MKT: SYN) KEITH A. MARKEY, PH.D., M.B.A. 212-514-7914 KMARKEY@GRIFFINSECURITIES.COM BUILDING ONE OF THE MOST COMPELLING
More informationSevion Therapeutics, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Sevion Therapeutics, Inc. Form: 8-K Date Filed: 2017-06-28 Corporate Issuer CIK: 1035354 Copyright 2017, Issuer Direct Corporation. All Right Reserved. Distribution
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationGlobal Leader in Bacteriophage Development to Combat Infectious Diseases
Global Leader in Bacteriophage Development to Combat Infectious Diseases September 13, 2016 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties
More informationGalena Biopharma, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationARCUSBIOSCIENCES,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,DC20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d) ofthesecuritiesexchangeactof1934 DateofReport(Dateofearliesteventreported):May9,2018 ARCUSBIOSCIENCES,INC.
More informationSage Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationVistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter.)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationJohn F. Kokai-Kun Digestive Disease Week Chicago, IL May 9, 2017
SYN-004 (Ribaxamase), an Oral β-lactamase, Prevented Clostridium difficile Infection and Protected Patients from Colonization by Antimicrobial Resistant Pathogens by Preserving Gut Microbiome Diversity
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationInvestor Presentation
Investor Presentation 2016 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use
More informationINTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationFORWARD LOOKING STATEMENTS
Jefferies 2014 Healthcare Conference November 19, 2014 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. Any statements contained herein which do not describe historical
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More informationLearning Tree International, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAntibiotics to Treat Multidrug-Resistant Bacterial Infections
Antibiotics to Treat Multidrug-Resistant Bacterial Infections Copyright 2017 Tetraphase Pharmaceuticals, Inc. C O M P A N Y P R E S E N T A T I O N A p r i l 2 0 1 7 TTPH Forward-Looking Statements and
More informationNasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
Nasdaq: MBRX Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 November 14, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationIDSA is pleased to offer the following comments on specific priority areas identified by FDA:
October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationTOKYO, JAPAN AND SOUTH SAN FRANCISCO,
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION March 2018 1 Forward Looking Statement This presentation includes statements relating to the company's Acuitas MDRO and Acuitas Lighthouse clinical laboratory services, FDA cleared
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationAntisense Therapeutics Ltd ASX:ANP January 2017
Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K/A (Amended Current report filing) Filed 09/28/05 for the Period Ending 09/26/05 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationALLIANCE DATA SYSTEMS CORPORATION (Exact Name of Registrant as Specified in Charter)
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationSYMBIOTIC HEALTH. Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics
SYMBIOTIC HEALTH Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics Contact: Gerard Honig PhD, Director ghonig@symbioticbio.com Overview Biotechnology startup
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More informationForm 8-K. Sally Beauty Holdings, Inc. - SBH. Filed: December 19, 2006 (period: December 19, 2006)
THE FOLLOWING INFORMATION, DOCUMENT OR REPORT IS BEING MADE AVAILABLE BY SALLY HOLDINGS LLC TO THE HOLDERS OF ITS 9.25% SENIOR NOTES DUE 2014 AND ITS 10.5% SENIOR SUBORDINATED NOTES DUE 2016 AS WELL AS
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More informationFirst Quarter 2018 Financial Results & Update
First Quarter 2018 Financial Results & Update April 26, 2018 Forward-Looking Statements and Non-GAAP Financial Information 2 Certain statements set forth in this presentation constitute forward-looking
More informationDisruptive Technology to Guide Precision Antibiotic Therapy
Disruptive Technology to Guide Precision Antibiotic Therapy Company Presentation, October 2018 Forward Looking Statement This presentation includes statements relating to the company's Acuitas AMR Gene
More informationSobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth. Investor Presentation l 13 November 2018
Sobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth Investor Presentation l 13 November 2018 Forward looking statements In order to utilise the Safe Harbor provisions
More informationTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
February 27, 2017 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Key Program Milestones Anticipated in 2017 and 2018 DUBLIN, Feb. 27,
More informationFORM 8-K. MCORPCX, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 1, 2017 ( February1,2017)
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationINVESTOR PRESENTATION. June 2018
INVESTOR PRESENTATION June 2018 Safe Harbor Statement This presentation contains forward looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationLehman Brothers Global Healthcare Conference
Lehman Brothers Global Healthcare Conference Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer March 20, 2007 Safe Harbor Except for the historical information contained herein, this
More informationInvitae Corporation (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 12, 2018 (Date
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationAURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March
More informationOral vaccines to protect patients against Clostridium difficile infection
Oral vaccines to protect patients against Clostridium difficile infection Jonathan Kearsey: Leads To Development Antibiotics and their alternatives-fixing and feeding the pipeline Project number: 601810
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationSPHERIX INCORPORATED (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationMelinta Therapeutics The Antibiotics Company
Melinta Therapeutics The Antibiotics Company January 10, 2018 Dan Wechsler, CEO Cautionary Note Regarding Forward-looking Statements This presentation contains forward-looking statements that involve a
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAntibiotics and alternative strategies to control infections
Antibiotics and alternative strategies to control infections http://blog.microbiologics.com/wpcontent/uploads/2015/12/acinetob acter-baumannii-232x300.jpg www.biochemj.org/bj/330/0581/bj3300581.htm ciss.blog.olemiss.edu
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationFORM 8-K. DRONE AVIATION HOLDING CORP. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationARADIGM CORP FORM 8-K. (Current report filing) Filed 08/29/13 for the Period Ending 08/27/13
ARADIGM CORP FORM 8-K (Current report filing) Filed 08/29/13 for the Period Ending 08/27/13 Address 3929 POINT EDEN WAY HAYWARD, CA 94545 Telephone 5102659000 CIK 0001013238 Symbol ARDM SIC Code 3845 -
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationKaryopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
August 4, 2016 Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to
More informationShionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S ), a Siderophore Cephalosporin
Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin Osaka, Japan, April 22, 2017 - Shionogi & Co., Ltd. today announced
More informationMobiquity Technologies, Inc.
SECURITIES & EXCHANGE COMMISSION EDGAR FILING Mobiquity Technologies, Inc. Form: 8-K Date Filed: 2012-03-13 Corporate Issuer CIK: 1084267 Symbol: MOBQ Fiscal Year End: 12/31 Copyright 2014, Issuer Direct
More informationDeveloping Bacteriophage Therapies for Patients with Antibiotic-Resistant Infections
Developing Bacteriophage Therapies for Patients with Antibiotic-Resistant Infections June 6, 2017 NYSE MKT: APHB Safe Harbor Statement This presentation contains forward-looking statements that involve
More informationADVANCING A NOVEL TREATMENT FOR SEPTIC SHOCK INVESTOR UPDATE
ADVANCING A NOVEL TREATMENT FOR SEPTIC SHOCK INVESTOR UPDATE April 2017 1 Forward Looking Statements Certain statements contained in this presentation constitute forward-looking information within the
More informationChimerix Announces First Quarter 2017 Financial Results
May 9, 2017 Chimerix Announces First Quarter 2017 Financial Results - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., May 09, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical
More informationUTILICRAFT AEROSPACE INDUSTRIES, INC.
UTILICRAFT AEROSPACE INDUSTRIES, INC. FORM 8-K (Current report filing) Filed 02/11/13 for the Period Ending 02/11/13 Address 401 RYLAND STREET, SUITE 200-A RENO, NV, 89502 Telephone 612-615-9334 CIK 0001334740
More informationAntibody against Chikungunya virus (mrna-1944)
Antibody against Chikungunya virus (mrna-1944) Modality Program # Program Indication Preclinical development Phase 1 Phase 2 Phase 3 and commercial Moderna rights mrna-1944 Antibody against Chikungunya
More information